Cervical cancer is almost entirely preventable through screening and HPV vaccination — yet it remains the most common cancer in Black South African women and a leading cause of cancer death. The reasons are systemic, but for women with medical aid, there is a clear opportunity: your scheme is legally required to fund cervical screening. Understanding when that benefit applies, how to access it, and what happens when a screening result is abnormal is the focus of this article.
What Is Cervical Screening?
Cervical screening aims to detect pre-cancerous changes in the cervix (cervical intraepithelial neoplasia — CIN) before they progress to invasive cancer. Two main screening tests are used:
The Pap Smear (cervical cytology): A sample of cells is collected from the cervix using a small brush or spatula. Cells are examined under a microscope for abnormal features. In SA, the traditional Pap smear remains widely used.
HPV DNA Test: A sample is tested for the presence of high-risk HPV strains (particularly HPV 16 and 18, and the other 12 high-risk strains). HPV DNA testing is more sensitive than cytology and is now preferred over Pap smear in updated international guidelines. Some SA private laboratories offer co-testing (HPV + cytology together).
Colposcopy: If a screening test is abnormal, a colposcopy is performed — a detailed examination of the cervix using magnification, with targeted biopsies. Colposcopy is the bridge between a screening abnormality and a diagnostic result.
LLETZ / Cone Biopsy: Treatment for CIN 2 or CIN 3 (high-grade pre-cancer). A loop excision (LLETZ) or cone biopsy removes the abnormal transformation zone. Highly effective at preventing progression to cancer.
SA-Specific Context: Why Screening Matters More Here
- Cervical cancer is the most common cancer in Black South African women (NCR).
- HIV-positive women are 5–10× more likely to develop cervical cancer and should be screened annually.
- A large proportion of SA cervical cancer diagnoses occur at Stage III–IV — because screening was missed or abnormal results were not followed up.
- Early detection (CIN 2/3, or Stage I cancer) is curative in almost all cases.
- Delay reduces the chance of cure and dramatically increases treatment cost.
Is Cervical Screening a PMB Benefit?
Yes. Cervical screening (Pap smear) is a PMB preventive benefit under the Medical Schemes Act. Specifically:
- Women aged 30 and over: Pap smear once every 3 years is a PMB preventive benefit.
- HIV-positive women: Annual Pap smear from the time of HIV diagnosis (regardless of age).
- HPV DNA test: Increasingly used as first-line screening; funding varies by scheme — confirm whether your scheme funds the HPV test specifically or only the cytology Pap smear.
What this means in practice: Your scheme must fund a routine cervical screening test at a DSP pathology lab once every 3 years (or annually for HIV-positive women) without charging it against your MSA or day-to-day benefits. This is separate from your available day-to-day benefit pool.
How to Access Your Free Cervical Screening
Many women with medical aid do not access their free screening because they don't know it exists or how to claim it. Steps:
- Confirm with your scheme: Call and ask: "How do I access my PMB preventive cervical screening benefit, and which pathology labs are in my DSP network?"
- Get a referral: Typically a GP referral or gynaecologist order is needed for the laboratory to process the sample under the PMB preventive benefit.
- Specify PMB billing: Ask the pathology lab to bill the test as a PMB preventive benefit — not against your MSA. This ensures it is processed correctly.
- Follow up the result: Ensure you receive and act on the result. Do not assume a normal result without seeing it.
What Happens If Your Screening Result Is Abnormal?
Abnormal results trigger a clinical pathway, each step of which has medical aid cover implications:
Low-grade abnormality (LSIL / CIN 1 / HPV positive, cytology normal): Usually managed with surveillance (repeat Pap or HPV test in 12 months). No immediate treatment required.
High-grade abnormality (HSIL / CIN 2 / CIN 3): Colposcopy + targeted biopsy is required. Colposcopy is a diagnostic procedure — funded from day-to-day benefits (if not classifiable as PMB diagnostic). Cost: R2,000–R5,000 private.
LLETZ or cone biopsy: If CIN 2/3 is confirmed on biopsy, treatment is indicated. LLETZ (loop excision) is typically done in the gynaecologist's rooms under local anaesthesia or as a day procedure under GA. Pre-authorisation is required. This is a PMB-funded procedure (surgical management of CIN as pre-invasive cervical pathology). Cost: R5,000–R12,000 (day procedure).
Post-LLETZ surveillance: More frequent Pap or HPV tests are required for 1–2 years after LLETZ. Cost: R600–R1,500 per test, funded from day-to-day benefits.
HPV Vaccination: Prevention Before Infection
Gardasil 9 (9-valent HPV vaccine) protects against the HPV strains responsible for ~90% of cervical cancers. It is most effective before the onset of sexual activity.
- Gardasil 9 cost: Approximately R600–R900 per dose.
- Doses required: 2 doses (for girls aged 9–14); 3 doses (for women 15+).
- Total cost: R1,200–R2,700 for the complete course.
- Medical aid funding: Most SA schemes do NOT fund Gardasil 9. Some comprehensive plans include it under a preventive care or vaccination benefit — check your specific plan documents. The public sector DoH administers free HPV vaccination to Grade 4 girls at government schools.
Even if you have been vaccinated, cervical screening is still required — no vaccine covers all high-risk HPV strains.
Day-to-Day Costs: What to Budget For
| Scenario | Estimated cost |
|---|---|
| Routine Pap smear (PMB — properly accessed) | R0 patient cost (PMB preventive) |
| HPV DNA test (if not specifically PMB-funded) | R600 – R1,500 |
| Colposcopy + biopsy (abnormal smear follow-up) | R2,000 – R5,000 |
| LLETZ (CIN 2/3 treatment) | R5,000 – R12,000 |
| Post-LLETZ surveillance Pap/HPV (1–2 years) | R600 – R1,500 per test |
| Gardasil 9 vaccination (full course) | R1,200 – R2,700 OOP |
Gap Cover Relevance
Gap cover is relevant if a gynaecological procedure (LLETZ, cone biopsy, hysteroscopy) is performed under general anaesthesia as a day procedure or as an in-hospital admission. Specialist shortfalls on the gynaecologist and anaesthesiologist are covered by gap cover. For routine outpatient screening and colposcopy, gap cover does not apply.
Key Questions to Ask Your Scheme
- How do I access my PMB cervical screening benefit, and which labs are my DSP?
- Does my scheme fund HPV DNA testing specifically, or only Pap cytology?
- Is LLETZ for CIN 2/3 funded as PMB?
- Does my plan fund Gardasil 9 vaccination?
- If I am HIV-positive, is my annual screening confirmed as a PMB benefit?
Talk to Eldon
Cervical screening is one of the few areas where your medical aid is genuinely obligated to cover a preventive cost. Make sure you are using this benefit. AURA can help you find a plan with strong preventive and women's health benefits.
See which plans pay for women's health →